A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants

Inclusion Criteria:

- Female participants are not of child-bearing potential

- Have a body mass index of 18 to 40 kilograms per square meter (kg/m^2)

- Participants with normal renal function - healthy as determined by medical history,
physical examination, and other screening procedures, with normal renal function
(assessed by estimated creatinine clearance [CLcr] greater than or equal to 90
milliliters per minute [mL/min] at screening)

- Participants with severe renal impairment - estimated CLcr less than 30 mL/min at
screening and are not undergoing hemodialysis

Exclusion Criteria:

- Have a history or presence of cardiovascular, respiratory, hepatic, renal,
gastrointestinal, endocrine, hematological, or neurological disorders capable of
significantly altering the absorption, metabolism, or elimination of drugs; of
constituting a risk when taking the study medication; or of interfering with the
interpretation of data

- Participants who are unwilling to comply with the dietary requirements/restrictions
during the study

- Hemoglobin less than 9 grams/deciliter (g/dL) or significant active hematological
disease from causes other than underlying renal disease